Search
ALECENSA 150 MG, Gélules
Details
| --- | Description |
|---|---|
| Pack | Boite de 224 ( 4 emballages de 56 unités ) |
| Strength (Dosage) | 150 MG |
| Laboratory | ROCHE S.A |
| Ingredients | Alectinib |
| Therapeutic class | Antinéoplasique, inhibiteur séléctif des kinases ALK et RET |
| ATC code | L01XE36 |
| PPH | $4,361.50 |
| PPV | $4,447.90 |
| Refundable | No |
| Refund base | $0.00 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Not specified |
| Uses | Alecensa est indiqué, en monothérapie, en première ligne de traitement des patients adultes ayant un cancer bronchique non à petites cellules (CBNPC) avancé avec un réarrangement du gène anaplastic lymphoma kinase (ALK-positif). Alecensa est indiqué en monothérapie dans le traitement du CBNPC avancé ALK-positif chez les patients adultes préalablement traités par crizotinib. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem